Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Am J Addict. 2017 Mar 22;26(4):319–325. doi: 10.1111/ajad.12527

Table 2.

Results among survey respondents (N=57)

1. “Study Completers” received all 3 injections
(N= 27)
2. Received 1–2 injections
(N=11)
3. Unsuccessful induction (0 injections)
(N= 19)
P*
Substance Use
Any opioid use following parent study 19 (70.4%) 9 (81.8%) 16 (84.2%) ns
Opioid use progressed to daily use 11 (40.7) 7 (63.6%) 16 (84.2%) 0.012 (1<2=3)
 • Time to daily opioid use (days) among those reporting any daily use since parent study 68.8 (+/− 30.7) 12.4 (+/− 32.4) 5.5 (+/− 10.7) <0.001 (1>2=3)
Any opioid use in past month of survey 8 (29.6%) 4 (36.4%) 6 (31.6%) ns
 • Heroin as primary opioid 4 (14.8%) 2 (18.2%) 6 (31.6%) ns
 • Injection drug use 0 (0%) 0 (0%) 4 (21%) 0.018 (3>1=2)
Past month cocaine use 3 (11.1%) 0 (0%) 0 (0%) ns
Past month marijuana use 7 (25.9%) 6 (54.5%) 2 (10.5%) 0.031 (2>3)
Past month alcohol use 15 (55.6%) 4 (36.4%) 4 (21.1%) 0.033 (1>3)
Past month nicotine use 16 (59.3%) 6 (54.5%) 5 (26.3%) 0.038 (1>3)
Overdose (none were fatal) 1 (4.8%) 0 (0%) 1 (5.3%) ns
Treatment Continuation
Received XR-NTX after study completion 13 (48.1%) 2 (18.2%) 0 (0%) 0.001 (1>3)
 • Number of injections received 6.5 (+/−3.7) 3 (+/−2.8) N/A ns
Active treatment (any, not including AA/NA) 7 (25.9%) 5 (45.5%) 8 (42.1%) ns
 • XR-NTX 6 (22.2%) 1 (9.1%) 0 (0%) 0.002 (1>3)
 • Buprenorphine 0 (0%) 2 (18.2%) 3 (15.8%) ns
 • Methadone 1 (3.7%) 1 (9.1%) 5 (26.3%) ns
 • Psychotherapy/groups 5 (18.5%) 1 (9.1%) 6 (31.6%) ns
Attitudes
Know someone on XR-NTX (past year) 11 (40.7%) 1 (9.1%) 6 (31.6%) ns
 • Reports positive effect 8 (29.6%) 1 (9.1%) 3 (15.8%) ns
Know someone on buprenorphine (past year) 19 (70.3%) 6 (54.5%) 13 (68.4%) ns
 • Reports positive effect 8 (29.6%) 2 (18.2%) 9 (47.4%) ns
Would recommend XR-NTX to others (agree/strongly agree) 24 (88.9%) 9 (81.2%) 11 (57.9%) 0.044 (1>3)
Barriers to continuing XR-NTX (among subgroup no longer receiving XR-NTX) N=21 N=10 N=19
Internal
 • “Felt cured” 11 (52.4%) 2 (20%) N/A ns
 • “Wanted to do it on my own” 5 (23.8%) 1 (10%) N/A ns
Side Effects 1 (4.8%) 6 (60%) N/A 0.002 (1<2)
External
 • Cost 4 (19%) 2 (20%) N/A ns
 • Lacked insurance reimbursement 3 (14.3%) 0 (0%) N/A ns